+1 (888) 794-0077
« Return

Grand Opening of New R&D Center in China

The Nanjing Branch of the DMPK Business Unit Begins Operation

Grand Opening

On May 24, 2021, the Nanjing Branch of the DMPK business unit of WuXi AppTec’s Laboratory Testing Division opened for business in a grand fashion. The event attracted many presenters, collaborators and guests, including Dr. Steve Yang, Co-CEO of WuXi AppTec, Mr. Peter Tong, COO of WuXi AppTec and other leaders.

The Nanjing branch of the DMPK business unit is comprised of a total construction area of about 8,000 square meters and is WuXi AppTec’s third DMPK site in China – in addition to the Shanghai and Suzhou sites.

Featuring radiolabeled ADME research, this center carries out in vitro ADME, in vivo pharmacokinetics (PK), preclinical mass balance studies, and the study of human absorption, metabolism and excretion with safety evaluation of metabolites. As a newly integrated DMPK service platform, the Nanjing branch will provide a full range of services that accelerate the R&D process from drug discovery to new drug application and meet customers’ diversified demand for ADME-PK testing services.

Opening Speech

Dr. Steve Yang, Co-CEO of WuXi AppTec, gave an opening speech. In it he stated, “WuXi AppTec’s new site in Nanjing will expand and strengthen the research capabilities of the DMPK platform to meet the diverse R&D needs of our customers, from drug discovery to clinical stage. Today’s opening ceremony is not only a milestone of our previous work, but also the beginning of our new journey. I sincerely hope that WuXi AppTec’s global platform and integrated portfolio of services will enable a great number of pharmaceutical companies, innovators, entrepreneurs, scientists and doctors to make progress with drug R&D more quickly and efficiently. Let us work together towards our vision ‘Every drug can be made and every disease can be treated’”

Opening Ceremony

This image has an empty alt attribute; its file name is DMPK-China-1.png

To mark the official opening of the new branch, several leaders and guests lit up the screen together. After the ceremony, guests were accompanied by technical experts on a visit to the new R&D center.

Scientific Forum

During the afternoon, the organizer held a scientific forum, featuring a series of presentations on the topics of DMPK research methodologies and new technical platforms, as well as how WuXi AppTec’s DMPK business unit developed its research platforms, infrastructures and capabilities over the last 16 years; an in-depth interpretation of NMPA’s new guidance on drug-drug interactions from an expert perspective; how the integrated WIND (WuXi AppTec IND) platform better enables successful IND submissions for customers; and the extraordinary data output delivered by QWBA technology at the Nanjing R&D Center.

Scientists and guests also discussed the DMPK methodologies of newly emerged modalities such as ADC, PROTAC and oligos, exploring how WuXi AppTec’s DMPK business unit closely followed international research frontiers, focusing on new modalities as part of the development and advancement of science and technology.

The grand opening ceremony was a great success, and we believe the Nanjing site will continue to innovate, making important contributions to the development of the pharmaceutical and health industry.

About the DMPK business unit of WuXi AppTec’s Laboratory Testing Division

As a business unit of WuXi AppTec’s Laboratory Testing Division, The DMPK business unit is mainly responsible for in vivo and in vitro pharmacokinetic (PK) research. With research and development centers in China (Shanghai, Suzhou, Nanjing) and the United States (New Jersey), we provide comprehensive pharmacokinetic research services from early discovery and preclinical development to clinical studies. Research services include in vitro absorption, distribution, metabolism and excretion (ADME) studies, in vivo pharmacokinetic studies, drug-drug interactions, metabolite identification (in vitro and in vivo biotransformation), quantitative autoradiography studies, human radiolabeled mass balance, and safety evaluation of metabolites.

Currently, the DMPK business unit has a research and development team of nearly 1,000 people, of which more than 60% have Doctor’s and Master’s degrees. With more than 15 years of experience, we serve more than 1,000 customers globally and have made over 500 successful investigational new drug (IND) applications.

Related Articles